Effectiveness of hydralazine/isosorbide dinitrate in racial/ethnic subgroups with heart failure

Clinical Therapeutics

Volumn 31, Issue 3, 2009, Pages 632-643

  Hammermeister, Karl E ^a   Fairclough, Diane ^a   Emsermann, Caroline Bublitz ^a   Hamman, Richard ^a   Ho, Michael ^b   Phibbs, Stephanie ^a   Plomondon, Mary ^b   Valuck, Robert ^a   West, David ^a   Steiner, John F ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b Denver VHA Medical Center   (United States)

Author keywords

African Americans; European continental ancestry group; heart failure; Hispanic Americans; hospitalization; hydralazine; isosorbide dinitrate; mortality; white

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; LOOP DIURETIC AGENT; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

AGED; ARTICLE; CARDIOVASCULAR RISK; COMORBIDITY; CONTROLLED STUDY; DRUG EFFICACY; ETHNICITY; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; RACE;

AFRICAN AMERICANS; AGED; DRUG COMBINATIONS; DRUG PRESCRIPTIONS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEART FAILURE; HISPANIC AMERICANS; HOSPITALIZATION; HUMANS; HYDRALAZINE; ISOSORBIDE DINITRATE; MALE; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VASODILATOR AGENTS; VETERANS;

EID: 64849087160     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.03.019     Document Type: Article

References (33)

1. Cohn J.N., Archibald D.G., Ziesche S., et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 314 (1986) 1547-1552
2. Cohn J.N., Johnson G., Ziesche S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325 (1991) 303-310
3. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators [published correction appears in N Engl J Med. 1992;327:1768]. N Engl J Med. 327 (1992) 685-691
4. Pfeffer M.A., Braunwald E., Moyé L.A., et al., for the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 327 (1992) 669-677
5. Køber L., Torp-Pedersen C., Carlsen J.E., et al., for the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 333 (1995) 1670-1676
6. Konstam M.A., Dracup K., Baker D.W., et al. Heart failure: Evaluation and care of patients with left ventricular systolic dysfunction. J Card Fail 1 (1995) 183-187
7. Hunt S.A., Baker D.W., Chin M.H., et al., for the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure); International Society for Heart and Lung Transplantation; and the Heart Failure Society of America. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation 104 (2001) 2996-3007
8. Hunt S.A., Abraham W.T., Chin M.H., et al., for the American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; and Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation; Endorsed by the Heart Rhythm Society. Circulation 112 (2005) e154-e235
9. Taylor A.L., Ziesche S., Yancy C., et al., for the African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure [published correction appears in N Engl J Med. 2005;352:1276]. N Engl J Med 351 (2004) 2049-2057
10. World Health Organization. International Classification of Diseases, Ninth Revision (ICD-9) (1977), Geneva, Switzerland, WHO
11. Bonow R.O., Bennett S., Casey D.E., et al., for the American College of Cardiology; American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures); Heart Failure Society of America. ACC/AHA clinical performance measures for adults with chronic heart failure. A report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures) endorsed by the Heart Failure Society of America. J Am Coll Cardiol 46 (2005) 1144-1178
12. Veterans Affairs Information Resource Center. VIReC research user guide: VHA pharmacy prescription data, 2003. http://www.virec.research.va.gov/References/RUG/RUG-Pharmacy03rev.pdf Accessed September 18, 2005
13. Sohn M.W., Arnold N., Maynard C., and Hynes D.M. Accuracy and completeness of mortality data in the Department of Veterans Affairs. Popul Health Metr 4 (2006) 2
14. Quan H., Sundararajan V., Halfon P., et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43 (2005) 1130-1139
15. Cox D.R. Regression models and life tables. J R Stat Soc. B34 (1972) 187-220
16. Fisher L.D., and Lin D.Y. Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health 20 (1999) 145-157
17. Allison P.D. Survival Analysis Using SAS: A Practical Guide (1995), Cary, NC, SAS Publishing
18. Zhou Z., Rahme E., Abrahamowicz M., and Pilote L. Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: A comparison of methods. Am J Epidemiol 162 (2005) 1016-1023
19. Elixhauser A., Steiner C., Harris D.R., and Coffey R.M. Comorbidity measures for use with administrative data. Med Care 36 (1998) 8-27
20. Solomon S.D., Anavekar N., Skali H., et al., for the Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 112 (2005) 3738-3744
21. Curtis J.P., Sokol S.I., Wang Y., et al. The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. J Am Coll Cardiol 42 (2003) 736-742
22. Bhatia R.S., Tu J.V., Lee D.S., et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355 (2006) 260-269
23. Owan T.E., Hodge D.O., Herges R.M., et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355 (2006) 251-259
24. Schneeweiss S., and Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 58 (2005) 323-337
25. McMahon A.D., Evans J.M., McGilchrist M.M., et al. Drug exposure risk windows and unexposed comparator groups for cohort studies in pharmacoepidemiology. Pharmacoepidemiol Drug Saf 7 (1998) 275-280
26. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: Immortal time bias in observational studies. Am J Respir Crit Care Med 168 (2003) 49-53
27. Shah B.R., Laupacis A., Hux J.E., and Austin P.C. Propensity score methods gave similar results to traditional regression modeling in observational studies: A systematic review. J Clin Epidemiol 58 (2005) 550-559
28. Austin P.C., Grootendorst P., and Anderson G.M. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: A Monte Carlo study. Stat Med 26 (2007) 734-753
29. Austin P.C., and Mamdani M.M. A comparison of propensity score methods: A case-study estimating the effectiveness of post-AMI statin use. Stat Med 25 (2006) 2084-2106
30. Glynn R.J., Schneeweiss S., and Stürmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 98 (2006) 253-259
31. Tam S.W., Sabolinski M.L., Worcel M., et al. Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: The V-HeFT paradox. Clin Pharmacokinet 46 (2007) 885-895
32. Lindenauer P.K., Pekow P., Wang K., et al. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med 353 (2005) 349-361
33. Lindenauer P.K., Pekow P., Wang K., et al. Lipid-lowering therapy and inhospital mortality following major noncardiac surgery. JAMA 291 (2004) 2092-2099